Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$1.20 USD
-0.09 (-6.98%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CATX 1.20 -0.09(-6.98%)
Will CATX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CATX
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Perspective Therapeutics (CATX)
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Perspective Therapeutics’ Board Elections and Stock Adjustments Approved
Perspective Therapeutics management to meet with Oppenheimer
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)